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Abstract 
Parkinson’s disease (PD) is a common neurodegenerative disease with a high degree of 
heterogeneity in its clinical features, rate of progression, and change of variables over 
time. In this work, we present a novel data-driven, network-based Trajectory Profile 
Clustering (TPC) algorithm for 1) identification of PD subtypes and 2) early prediction of 
disease progression in individual patients. Our subtype identification is based not only on 
PD variables, but also on their complex patterns of progression, providing a useful tool for 
the analysis of large heterogenous, longitudinal data. Specifically, we cluster patients 
based on the similarity of their trajectories through a time series of bipartite networks 
connecting patients to demographic, clinical, and genetic variables. We apply this 
approach to demographic and clinical data from the Parkinson’s Progression Markers 
Initiative (PPMI) dataset and identify 3 patient clusters, consistent with 3 distinct PD 
subtypes, each with a characteristic variable progression profile. Additionally, TPC 
predicts an individual patient’s subtype and future disease trajectory, based on baseline 
assessments. Application of our approach resulted in 74% accurate subtype prediction in 
year 4 in a test/validation cohort. Furthermore, we show that genetic variability can be 
integrated seamlessly in our TPC approach. In summary, using PD as a model for chronic 
progressive diseases, we show that TPC leverages high-dimensional longitudinal datasets 
for subtype identification and early prediction of individual disease subtype. We anticipate 
this approach will be broadly applicable to multidimensional longitudinal datasets in 
diverse chronic diseases.  
Introduction 
Parkinson’s disease (PD) is the most common neurodegenerative movement disorder, 
affecting an estimated 7-10 million people worldwide1. The cause of PD is unknown, and 
the disease course is variable with age of onset and rate of progression differing across the 
population2. Furthermore, the clinical presentation is variable, with a broad range of 
possible motor and non-motor symptoms3. Based on these differences, multiple PD 
subtypes have been proposed, based on clinical intuition or unbiased data-driven 
approaches like cluster analysis4. There is currently no consensus on which subtypes are 
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biologically valid and clinically relevant, and the best approach for identifying such 
subtypes remains elusive5. Lack of integration of the longitudinal data for a large number 
of variables is a limitation of existing approaches.  
Network medicine6-10 offers a promising approach for untangling the complexities due to 
multiple influences on disease via analysis of interconnections within data. For example, 
studies of the human disease network (i.e. the ‘diseaseome’)10, in which diseases are 
linked if they share one or more associated genes, are useful for identifying disease 
pathways and predicting other disease-related genetic variants8. With a few exceptions, 
most network medicine studies have focused on biomolecular data10-13 rather than the 
complexities of clinical phenotypic assessments, and disease subtyping based on disease 
progression patterns is relatively unexplored14,15. Additionally, a large number of genetic 
variants have been identified as risk factors to develop PD. Recently, evidence has 
emerged that the same genetic risk variants also determine certain clinical features of the 
disease16,17. Genetic factors likely play a major role in determining PD subtypes, however, 
little work has been done to incorporate genetic data into data-driven algorithms to 
identify subtypes. One related recent study described inclusion of genetic data to predict 
the annual rate of change in combined scores from the Movement Disorder Society-
Unified Parkinson’s Disease Rating Scale16.  
Technological advances in data processing and storage capacity have enabled 
development of large clinical datasets, containing longitudinal clinical and biological data. 
In this work we use data from the Michael J. Fox Foundation’s Parkinson’s Progression 
Markers Initiative (PPMI), a worldwide study to establish a comprehensive set of clinical, 
imaging and genetic data (http://www.ppmi-info.org). Such datasets require sophisticated data-
driven approaches for effective extraction and analysis of clinically relevant information. 
Data-driven methods are typically applied to diseases in two ways: disease-specific, i.e., 
identifying disease subtypes and variable progression patterns from large scale patient 
data, and patient-specific, i.e., predicting disease subtype and trajectory in the individual 
patient based on their data. Our work incorporates both these perspectives and presents a 
network science method that not only identifies disease subtypes using diverse types of 
patient data (e.g., genetic and clinical variables), but also is predictive. We present our 
results based on a (PD dataset, however this method is easily applied to other chronic 
medical conditions. 
To provide an intuitive data-driven solution that is both disease- and patient-centric, we 
develop the Trajectory Profile Clustering (TPC) algorithm to identify PD subtypes through 
similarities in patterns of progression. With this approach, we identify three PD subtypes. 
Additionally, we demonstrate the predictive ability of our algorithm on a test/validation 
cohort of new patients. Our method correctly predicts the individual PD subtype four 
years in advance, in 74% of the population. We also explore inclusion of four PD genetic 
variants in our approach, to demonstrate its capacity to simultaneously incorporate 
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clinical, demographic, and genetic information.  
This work is aimed at bridging the gap between the computational methodologies 
developed by network and data scientists and the clinical experience of health 
professionals.  
Results 
Description of Data 
Table 1: PPMI Data used in this study include two demographic variables, outcome 
variables from six clinical domains, and four genetic single nucleotide polymorphisms. 
Additional description of the measures found at http://www.ppmi-info.org.  
Data used in the preparation of this article were obtained from the Parkinson’s Progression 
Markers Initiative (PPMI) database (www.ppmi-info.org/data). Of the 430 patients at 
baseline in this dataset, 314 patients remained in year 4. Once patients with incomplete 
data were excluded, 198 patients remained for our analysis. Twenty percent of the sample 
Domain Scale/Variable
Genetic Risk Loci
 rs11060180
 rs6430538
 rs823118
 rs356181
G1
G2
G3
G4
General PD Severity
 Movement Disorders Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) - Part 1
 Movement Disorders Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) - Part 2
 Total Movement Disorders Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) 
Demographics
Gender
Age
 Movement Disorders Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) - Part 3
Autonomic
 Scales for Outcomes in Parkinson’s Disease - Autonomic
Mental Health
 Geriatric Depression Scale
 State -Trait Anxiety Inventory
Disability
 Schwab and England Activities of Daily Living
SCOPA-AUT
 Epworth Sleepiness Scale
 Rapid Eye Movement Sleep Behavior Disorder Questionnaire
Sleep
RBDQ
ESS
GDS
STAI
MDS-UPDRS1
MDS-UPDRS2
MDS-UPDRS3
T-MDS-UPDRS
SEADL
Cognitive
 Hopkins Verbal Learning Test
 Benton Judgement of Line Orientation
Letter Number Sequencing
 Montreal Cognitive Assessment
 Symbol Digit Modalities Test
 Semantic Fluency Test
JOLO
SDM
MoCA
HVLT
LNS
SFT
Gender
Age
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population (n=38) was kept as a test/validation dataset. The remainder of the patients 
(n=160) form the training dataset that was used in the algorithm to identify PD subtypes. 
The data included demographics, clinical outcome variables from six clinical domains 
(General PD Severity, Disability, Cognition, Autonomic Function, Sleep, and Mental 
Health) and 4 PD genetic variants (Table 1).  
Trajectory Profile Clustering Algorithm 
Fig. 1: (left) An illustration of an individual-variable bipartite graph at one timestep. 
(right) Set of bipartite graphs across time. 
Our Trajectory Profile Clustering (TPC) Algorithm is designed to group together patients 
based on the similarities of their disease trajectories. The algorithm proceeds as follows: 
1. Create bipartite networks connecting individuals to variables: At a single point in time 
t (e.g., baseline, year 1, year 2, etc.) we construct an N×V bipartite graph indicating the 
connections between individuals and disease variables, where N is the number of 
individuals in the population and V is the total number of variables measured, as 
illustrated in Fig. 1. For M time points, we can represent the set of these bipartite 
graphs as an N×V×M multidimensional array, where Xivt gives the value of individual 
i’s disease variable v at time t.  
2. Transform data so that higher values are associated with disease progression: For each 
variable, we determine its ‘direction.’ If higher values of the variable are associated with 
greater disease severity then direction for the vth variable is given by dv = +1, otherwise 
dv = −1. We then define a new N×V×M multi-dimensional array Y such that Yivt=dv 
Xivt. 
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3. Construct patient trajectory profiles: For each patient i, we construct a V x M 
trajectory profile matrix, Ti. The matrix entries of Ti are calculated as follows: 
• For non-binary variables:  
 = 1  if Yivt >θv                                  (1) 
                       = 0  otherwise  
where Yivt  is defined as described above and θv is the threshold for the continuous 
variable v that corresponds to the 50th percentile or median for Y across the 
population in the baseline (t=0 for our data).For non-binary variables 
• For binary variables:  
  For gender:   = 1 if the patient is male,   = 0 otherwise 
 For  genetic risk loci:  = 1 if patient contains single nucleotide polymorphisms 
 (SNP) v; !  = 0 otherwise. Each SNP is treated as independent.  
4. Create a patient-patient network with connections based on trajectory similarity: After 
having defined the trajectory profile matrix Ti for each individual i, we create a 
patient-patient network P of all patients in the training set with an adjacency matrix 
given by:  
! .  (2)                    
In other words,   gives the number of matrix entries for which Ti has the same    
value as Tj.   This formulation implies that all variables are equally important. If we 
wanted to have different weights across variables and across the years, we can instead 
set  where wvt is the weight of variable v at time t. 
5. Cluster the network to identify communities/subtypes: We then perform Louvain 
community detection18 to maximize the Newman-Girvan modularity function19 on the 
uni-partite network defined by the weighted matrix P. This allows us to cluster 
trajectory profiles, and hence patients, into communities (subtypes).  
6. Construct aggregate profiles to characterize each community/subtype: We average the 
trajectory profiles of all patients in each community !   to obtain the ‘community/
subtype profile’ ! , a V x M matrix with elements defined by 
      !   (3) 
where  Nl  is the total number of individuals in community .  is a normalization 
constant that represents the average value for variable v in the baseline:
Tivt
T ivt T ivt
T ivt
T ivt
Pij =∑
v,t
(Tivt = = Tjvt)
Pij
Pij =∑
v,t
wvt(Tivt = = Tjvt)
Cl
Sl
Slvt =
∑i∈Cl T
i
vt
NlUv0
Cl Uv0
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! , and again, 0 denotes the baseline year.  
Prediction Scheme for Test Patients 
From baseline data, we predict the community/subtype that an individual test patient 
(patient whose data was not used in identifying the PD subtypes) belongs to. We then 
check whether the test patient is still aligned with the same community/subtype after 4 
years to demonstrate the utility of our baseline prediction.   
To predict test patient i’s subtype from his/her baseline profile, we find the community 
(subtype) !  whose baseline community profile, with elements ! , has the smallest 
Euclidean distance from the patient’s baseline profile. In other words, l is chosen to 
minimize the distance  
!        (4) 
Does the patient’s trajectory match the subtype’s trajectory?  We then investigate the 
quality of the subtype/community baseline prediction at a later time t by calculating the 
patient’s subtype/community Cl’ such that l’ is chosen to minimize the distance between 
the community profile and the patient’s profile at time t: 
!        (5) 
The prediction accuracy is then defined as the fraction of test patients for which the 
subtype identification (l) from the baseline matches the subtype identification (l’) at a later 
time t.  
TPC Algorithm for PD Subtype identification 
In this section, we present the disease subtypes (communities) identified by our method 
from the training patient data. Maximizing Newman-Girvan modularity on the patient-
patient trajectory profile network gives us three distinct subtypes.  
The darkness of the shade of grey of a continuous variable in a year denotes the fraction of 
the subtype population that has a value above the median of the total population baseline 
for that variable. The darkness of the shade of a grey for a binary variable is the fraction of 
the subtype population containing that variable (male in the case of the variable gender). 
Uv0 =
∑i T
i
v0
N
Cl Slv0
d il0 = ∑
v
(Tiv0 − Slv0)2
dil′ t = ∑
v
(Tivt − Sl′  vt)2
!7
For some scales or tests, a higher score implies a healthier/less severely affected patient 
(such as the Montreal Cognitive Assessment), while for other scales, the opposite is true 
(higher score = greater severity). Therefore, in step one of our algorithm we normalized 
the data, so that for all variables except for the genetic and demographic variables, a 
higher score is associated with greater severity of that variable and a deeper shade of grey. 
Figure 2: Subtypes/communities identified by our algorithm: The top three panels show 
three subtype/community profiles (average profile of all patients in the subtype). Subtypes 
identified by the algorithm containing fewer than 10 patients are not shown. The bottom 
panel shows the total population profile. The shade of grey indicates the affected fraction, 
i.e, fraction above baseline median in the direction of disease progression for the 
continuous variables, and fraction that is male for gender. n is the number of patients in 
the subtype. The variable names are listed below the panels (See Table 1 for description). 
Description of the Subtypes 
Subtype 1 is small (n=22), largely female and relatively young. Subtype 2 is the largest 
(n=72) with a milder disease course on measures of general PD severity, mental health, 
autonomic function and sleep, and a similar cognitive profile as Subtype 1. Subtype 3 
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shows a clearly different cognitive profile with better scores on some cognitive variables 
(SFT, HVLT, LNS), but worse scores on others (JOLO, SDM, MoCA). Subtype 3 is fairly 
large (n=61), largely male and older, with greater severity in variables describing general 
PD severity, sleep, autonomic function and mental health.  Interestingly, the six cognitive 
variables split into two sub-categories (Cog I: JOLO, SDM, MoCA and Cog II: SFT, 
HVLT, LNS) especially in subtypes 2 and 3. The bottom panel in Figure 2 shows the 
profile of the total population. Since the threshold variable severity in an individual is set 
with respect to the median of the total population at baseline, the total population baseline 
profile for all variables has a value close to 0.5 (i.e., 50% of the total population at 
baseline has a value of 1 for any variable, and the other half has a value of 0). Fluctuations 
of the baseline total population value around 0.5 may occur if the precise value of a 
variable in the baseline year for multiple people coincides with the variable median of the 
entire population. 
Early Prediction of Patient Subtypes 
In addition to identifying PD subtypes, our method predicts the individual patient subtype 
years in advance. In this section the test patient cohort (n=38) is used to assess the 
accuracy of early prediction of disease subtype.  Data from these test patients is not used 
in the identification of the subtypes.  
Figure 3: Prediction of test patients into the subtypes identified in Figure 2. The ith panel 
(row) shows the distance between the test patient ith year profile and the ith year subtype 
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profile (shape coded). The predicted subtype for each individual (subtype with minimum 
baseline-year distance) is colored red to allow for tracking across the years (panels). 
Prediction accuracy in year 4 is 74%. Data includes 38 test patients and 18 clinical 
variables across 5 time points: baseline (bl)  or year 0 + years 1,2,3,4. 
Figure 3 shows the prediction of future PD subtype based on baseline data for 38 test 
patients that run across the horizontal axis. The top panel shows the Euclidian distance 
between the baseline profile of a patient and the baseline profile of each subtype (subtypes 
are shape coded). The subtype with which the patient has minimum baseline distance is 
the ‘predicted subtype’, and is marked in red. Patients are organized from left to right in 
order of decreasing confidence, i.e., from minimum to maximum distance of the patients’ 
baseline profile with the predicted subtype baseline profile. The remaining panels 
represent subsequent years, plotting the distance between the patient profile and subtype 
profiles in corresponding years. The red coding of predicted community makes it easy to 
track across the years. Finally, in year 4, we assess the accuracy of our predictions. If the 
subtype with minimum distance to the patient in year 4 is the same as the originally 
predicted subtype, then we consider our prediction to be successful for that patient. In 
other words, if in year 4 the red subtype for a patient is below the black subtypes then our 
prediction is successful. For the newly diagnosed PD patients in the PPMI dataset, our 
algorithm predicts the PD subtype after 4 years of disease progression with 74% accuracy.  
Incorporating Genetic Data into the TPC Algorithm 
Figure 4: (a) The top five panels show three average community (subtype) profiles C 
normalized by the total population baseline year (year 0), identified by our TPC algorithm. 
Subtypes identified by the algorithm containing less than 10 patients are not shown. The 
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bottom panel shows the total population profile. The legend is a measure of the affected 
fraction, i.e, fraction above baseline median in the direction of disease progression for the 
continuous variables, and fraction that is male and fraction containing the genetic SNP for 
gender and genetic variables respectively. n is the number of patients in the community. 
(b) The mth panel shows the distance between the test patient mth year profile and the mth 
year profile of the subtypes (shape coded). The predicted subtype for each individual 
(subtype with minimum baseline distance) is colored red to allow for tracking across the 
years (panels). Prediction accuracy in year 4 is 64%. Data includes 38 test patients and 18 
clinical variables across 5 time points: baseline (bl)  or year 0 + years 1,2,3,4. 
Genetic variants are increasingly recognized as important determinants of disease subtype 
and disease progression and prognosis. As an exploratory objective, we investigated the 
integration of genetic variants (single nucleotide polymorphisms, or SNPs) in previously 
identified PD risk loci into our TPC-based approach. Each patient has 2 copies for each 
piece of genetic information, and there are by definition 2 variants for each SNP. Hence, 
there are 3 possible combinations of the 2 variants for each of the genetic risk loci. PPMI 
contains information for 28 such SNPs for each patient. We chose 4 of those 28 loci to be 
included in our approach as a proof-of-principal. For one of those loci (rs356181/2), an 
association with PD motor subtype has recently been described,17 making this an obvious 
choice for our study. In the absence of any established genotype-phenotype correlation for 
any of the other risk loci, we picked the additional 3 SNPs based on their high minor allele 
frequency, so that all 3 possible combinations of the 2 genetic variants were present in 
sufficient numbers in our study population of 198 subjects.   
Figure 4 shows the five subtypes identified when genetic data is introduced. The plots 
Figure 4 (a,b) are organized in the same way as Figures 2 and 3 respectively. In Figure 
4(a), the darkness of the shade of grey of a variable in a year denotes the fraction of the 
subtype that has a value above the baseline median of the total population of that variable. 
Subtypes 1 (top) and 4 have relatively mild disease profiles, with the CC allele of G2 
being more frequent in subtype 1 (top), and the CT allele of G1, TT allele of G2, and TT 
allele of G4 being frequent in community 4. Subtypes 2 and 3 have alternate sets of 
cognitive variables dominating, a feature also observed in Figure 2. Subtypes 3 and 4 are 
the youngest, whereas 2 and 5 are the oldest. Subtype 2 has a larger population (38) and is 
the subtype with the maximum fraction of patients that have above average severity of the 
variables (darker grey shade). Subtype 5 has less psychiatric symptomatology but 
intermediate motor (MDS-UPDRS3) and cognitive dysfunction. Each of the subtypes has 
a distinct genetic profile. When genetic data is added to the analysis, prediction of patient 
subtype in the test group shows an accuracy of 64%. This is 10% less accuracy of 
prediction than obtained when using only the clinical data. 
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Discussion 
Multidimensional clinical datasets are valuable resources that are not used to their full 
potential due to the analytic challenges of diverse biomarkers and outcome variables. We 
describe development of a method to identify disease subtypes based on the pattern of 
progression of multidimensional clinical data including demographics, clinical variables, 
and genetics. We then validate our method by measuring the accuracy of subtype 
prediction in individual patients based on baseline clinical and genetic variables.  
The disease subtypes are characterized by patterns of progression of the clinical variables. 
The concordance between our agnostic results with the domain-structure of the variables 
supports our approach. For instance, in the analysis on identifying PD subtypes, in spite of 
treating the variables independently, all the variables in the General PD severity domain 
show similar trends in each subtype. For example, subtypes 1 and 3 have high progression 
of all PD severity variables and subtype 2 has a low progression of all PD severity 
variables. Variables of other domains such as Sleep, Mental Health and Cognition show 
similar trends within a subtype (although Cognitive shows an additional layer of 
differentiation into Cog I and Cog II).  
Our predictions of the future subtype of individual patients in the test sample based on 
their baseline data, shows good accuracy in predicting disease subtypes four years later 
(74% for clinical data and 64% for clinical+genetic data). The explanation for the 
reduction in predictive accuracy with addition of genetic data may be due to: 1) the 
inclusion of a very limited number of genetic risk loci, 2) that SNPs are more potent 
predictors of risk in PD than the clinical phenotype, 3)  that genetic data isn’t predictive of 
PD subtype within the 4-year time frame of our data or 4) that the genetic data has a large 
variance in the population, thus requiring a larger dataset for long-term prediction (the 
larger number of subtypes found by our method may indicate this). Nonetheless, this 
exploratory work successfully demonstrates the inclusion of genetic data in this approach. 
Other biomarkers (i.e. serologic and cerebrospinal fluid biomarkers) can also be easily 
integrated into our analysis. Our algorithm is likely to benefit from more extensive 
datasets with larger populations. 
A number of studies have identified PD subtypes based on baseline characteristics20-22. In 
this work, we used the longitudinal data to identify disease subtypes, and defined the 
baseline characteristics of the subtypes retrospectively. The baseline features of individual 
patients were then used in a test cohort to predict the future disease trajectory (prognosis). 
To our knowledge, this is a novel approach21. Our study represents an innovative 
approach, that has advantages over previous methods by taking full advantage of large 
heterogenous, longitudinal datasets.  
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Our trajectory clustering method works with various types of data including clinician- and 
patient-reported outcome measures, genetic alleles, physical performance measures, as 
well as diverse results from diagnostic investigations. This first approach uses 
demographics, clinician- and patient-reported data, and genetic data. In this analysis, each 
genetic SNP and clinical variable is treated independently and allotted the same weight. 
Our algorithm allows for variable weightings, where each domain and SNP is assigned a 
chosen weight. However, this raises the question of how the weighting would be decided. 
For example, if we had allotted equal weights to one hundred SNPs in our analysis in 
addition to the 18 clinical variables, the genetic information would dominate the 
algorithm, and affect the resulting communities. On the other hand, different weighting 
strategies may be preferable based on the study aims. For example, if the main objective is 
to identify disease subtypes based on motor vs. cognitive function, one could allot equal 
cumulative weight to the motor and cognitive domains.  
A strength of our algorithm, which is also a caveat, is that it is entirely data-driven. The 
level of severity of each variable relative to the baseline median is used to normalize all 
variables, as opposed to the absolute value of the variable. This is done so as to readily 
compare changes in different variables. A notable example is the clinical variable, SEADL 
(a disability scale). SEADL is a relatively insensitive scale in the early years of PD since 
there is little functional disability in the years following diagnosis.  Yet, in our analysis 
SEADL shows high progression (darker shade in later years) in Figures 2 and 4(a). It is 
important to note that this dark shade isn’t indicative of the absolute severity. It only tells 
us that a larger fraction of the population in the later years has SEADL values above the 
baseline mean (which may be low to begin with).  
Our approach is innovative, adaptable, and clinically relevant.  PD subtyping24 is an area 
of active research but there are currently no clinically prognostic analyses in use in the 
management of PD.  Reliable prognostic analyses will change clinical management by 
informing earlier, more aggressive management and improving prognostic counseling. A 
natural extension of this work involves implementing the method for datasets in other 
chronic medical conditions. Another interesting direction involves extending the TPC 
algorithm to incorporate and compare other network clustering approaches, such as multi-
layer network clustering25. Other future directions include studies of the effect of 
treatment on progression of disease variables, and predicting modifications of algorithm-
identified subtypes as a consequence of different treatments. 
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